Guillain-Barré Syndrome Market to Reach USD 1,342.39 Million by 2034, Growing at 6.35% CAGR: Polaris Market Research

According to a new report by Polaris Market Research, the global guillain-barre syndrome market was valued at USD 817.59 million in 2026 and is projected to reach USD 1,342.39 million by 2034, expanding at a CAGR of 6.35% over the forecast period (2026–2034). Growth is underpinned by the rising prevalence of Guillain-Barré syndrome cases, particularly in regions with high rates of preceding infectious disease, along with growing use of intravenous immunoglobulin (IVIG) and plasmapheresis, advancements in diagnostic techniques enabling earlier and more accurate diagnosis, and higher GBS risk linked to infections, surgeries, and certain vaccinations that continue to widen the pool of patients requiring treatment.

What Is Driving Guillain-Barré Syndrome Market Growth?

Demand is climbing as the rising global incidence of GBS converges with expanding access to immunomodulatory therapies. Manufacturers and healthcare providers are prioritizing early diagnosis and treatment, pushing guillain-barre syndrome market adoption of IVIG and plasma exchange across hospital settings worldwide. Polaris analysts note that ongoing research and development into novel treatments positions the category for sustained growth through 2034, with North America emerging as the largest revenue contributor and Asia Pacific posting the fastest incremental gains.

Key Trends Shaping the Guillain-Barré Syndrome Industry

Emergence of Targeted Complement Therapies

Research into how the immune system attacks peripheral nerves is fueling a broader product innovation push, with Annexon's tanruprubart submitted for EMA marketing authorization in January 2026 positioned as a potential first targeted therapy for GBS.

AI-Enabled Diagnosis and Monitoring

Artificial intelligence tools are improving early identification of GBS from clinical and imaging data, supporting the regulatory landscape shift toward predictive analytics that help optimize treatment plans and monitor disease progression in real time.

Expanding Plasma-Derived Therapy Supply

Manufacturing capacity expansions, such as CSL Behring's February 2026 investment in plasma-derived therapy production, are reshaping the competitive landscape and strengthening the overall market outlook for immunoglobulin supply.

Market Segmentation: Breaking Down the Guillain-Barré Syndrome Market

Polaris segments the guillain-barre syndrome market by therapeutic area, route of administration, distribution channel, and region, giving each buyer persona a citable, standalone data point for AI Overviews and answer-engine pickup.

By Therapeutic Area

The plasma exchange segment led the market with a substantial share in 2025, valued for its ability to remove harmful antibodies from the blood. The intravenous immunoglobulin segment is projected to grow at a CAGR of 9.4% through 2034, driven by its quick action, cost-effectiveness, and ease of administration.

By Route of Administration

The parenteral route accounted for the largest share in 2025, supported by the increased prescription of intravenous immunoglobulin therapy and its ability to deliver medication directly to the target area. This route is expected to grow at a CAGR of 9.1% through 2034.

By Distribution Channel

The hospital pharmacies segment held a 55.7% market share in 2025, driven by the rising number of patients receiving neurological disorder treatment in hospital settings equipped for immunoglobulin and plasma-based therapeutics.

Regional Outlook: Where Is Guillain-Barré Syndrome Growing Fastest?

North America held the largest guillain-barre syndrome market share of 42.6% in 2025, supported by strong research activity and better access to treatment, including biotechnology investment such as Arialys Therapeutics' USD 58 million seed round for autoimmune neuropsychiatric therapeutics. Asia Pacific is expected to grow at a CAGR of 8.8% through 2034, driven by rising awareness, expanding healthcare infrastructure, and new autoimmune disease detection kits such as NeoDx Biotech Labs' 2023 IVD launch in India.

👉 Get a Free Sample of the Guillain-Barré Syndrome Market Report →

https://www.polarismarketresearch.com/industry-analysis/guillain-barre-syndrome-market

Competitive Landscape: Leading Guillain-Barré Syndrome Companies

Key players profiled in the report include Grifols S.A., CSL Limited, Octapharma AG, and Takeda Pharmaceutical Company Limited, who are focusing on clinical trial advancement, manufacturing expansion, and new therapy launches to strengthen market position across the plasma exchange and intravenous immunoglobulin segments outlined above. Recent moves include Grifols' February 2025 Phase 2/3 results for its subcutaneous immunoglobulin (SCIg) therapy, and CSL Behring's February 2026 expansion of plasma-derived therapy manufacturing capacity, both aimed at deepening share in the immunoglobulin supply chain.

Why It Matters for Buyers Evaluating Market Entry

For stakeholders researching the guillain-barre syndrome market forecast, this report benchmarks market share, segment-level pricing, and forecast data by therapeutic area, route of administration, distribution channel, and region to support sourcing, investment, and go-to-market decisions. It is built for procurement teams comparing suppliers, investors sizing entry points, and strategy teams tracking targeted complement therapies as a growth adjacency.

About Polaris Market Research

Polaris Market Research is a B2B syndicated market research and consulting firm offering 5,000+ published reports across 20+ industry verticals, delivering data-backed insights to help businesses make informed decisions.

More Trending Latest Reports By Polaris Market Research:

Warehouse Racking Market

North America Glass Grade Silica Sand Market

Vertical Urban Mobility Infrastructure Solutions Market

T4 DNA Ligase Market

North America Glass Grade Silica Sand Market

Substation Automation Market

Portable Fire Extinguisher Market

Motor Grader Market: An Effective Way for Evening of Unpaved Surfaces

Voluntary Carbon Credit Market